Scholarlink

Introduction <p>Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly affects the quality of life (QoL). Lebrikizumab, a biologic drug targeting interleukin-13, demonstrated efficacy and safety in clinical trials. However, real-world data remain limited, largely restricted to Asian populations.</p> Methods <p>This 16-week retrospective multicenter study included 78 adults from a predominantly white cohort with moderate-to-severe AD treated with lebrikizumab throughout 2024. Patients were both naïve and experienced with biologics or Janus kinase inhibitors (bio/JAKi-naïve or -experienced). The primary outcome for disease severity and therapeutic response was measured using the Eczema Area and Severity Index (EASI). Secondary outcomes included the Dermatology Life Quality Index (DLQI), itch- and sleep-numerical rating scales (NRS), body surface area (BSA), Investigator Global Assessment (IGA), SCORing Atopic Dermatitis (SCORAD), and Patient-Oriented Eczema Measure (POEM). Atopic Dermatitis Control Tool (ADCT) and minimal disease activity (MDA) were used to estimate disease control, and Hospital Anxiety and Depression Scales to monitor mental health status.</p> Results <p>At week&#xa0;16, benefits in disease severity were observed for EASI (− 15.8 ± 9.4, <i>p</i> &lt; 0.0001) and EASI head and neck (− 2.0 ± 1.7, <i>p</i> &lt; 0.0001). QoL significantly improved in 70% of patients (DLQI reduction of − 12.6 ± 9.3, <i>p</i> &lt; 0.0001), accompanied by decreased pruritus (Itch-NRS reduction of − 4.6 ± 3.2, <i>p</i> &lt; 0.0001) and better sleep quality (sleep-NRS reduction of − 4.1 ± 3.4, <i>p</i> &lt; 0.0001). A 76% reduction in BSA score was recorded, 85% of subjects improved their IGA index, with 62% achieving a score of 0–1, and SCORAD and POEM assessments significantly improved (<i>p</i> &lt; 0.0001). Patients perceived a better control of the disease (ADCT, − 10.9 ± 7.1, <i>p</i> &lt; 0.0001), and 14% of patients achieved MDA. Anxiety and depression levels decreased. Four mild adverse events were registered.</p> Conclusions <p>This is one of the first real-world multicenter studies in a predominantly adult white population showing that lebrikizumab is effective, safe and improves symptoms, QoL, and mental health in moderate-to-severe AD bio/JAKi-naïve and -experienced patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月10日

查看全文
  • Gianluca Avallone,
  • Andrea Bombelli,
  • Luigi Gargiulo,
  • Caterina Foti,
  • Ilaria Trave,
  • Mariateresa Rossi,
  • Elisabetta Magnaterra,
  • Flavia Pigliacelli,
  • Piergiorgio Malagoli,
  • Serena Giacalone,
  • Antonio Portarapillo,
  • Cataldo Patruno,
  • Natale Schettini,
  • Laura Bonzano,
  • Elena Pezzolo,
  • Camilla Chello,
  • Niccolò Gori,
  • Giovanna Brunasso,
  • Federica Veronese,
  • Michela Ortoncelli,
  • Ersilia Tolino,
  • Alan Azzolini,
  • Francesco Bellinato,
  • Katharina Hansel,
  • Eugenia Veronica Di Brizzi,
  • Carlotta Gurioli,
  • Maria Esposito,
  • Roberta Giuffrida,
  • Francesca Barei,
  • Paolo Calzari,
  • Anna Graziella Burroni,
  • Massimo Gola,
  • Maria Mariano,
  • Maria Concetta Fargnoli,
  • Maddalena Napolitano,
  • Teresa Grieco,
  • Ketty Peris,
  • Paola Savoia,
  • Simone Ribero,
  • Giampiero Girolomoni,
  • Luca Stingeni,
  • Anna Balato,
  • Antonio Costanzo,
  • Angelo Valerio Marzano,
  • Alessandra Narcisi,
  • Silvia Mariel Ferrucci

摘要

Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly affects the quality of life (QoL). Lebrikizumab, a biologic drug targeting interleukin-13, demonstrated efficacy and safety in clinical trials. However, real-world data remain limited, largely restricted to Asian populations.

Methods

This 16-week retrospective multicenter study included 78 adults from a predominantly white cohort with moderate-to-severe AD treated with lebrikizumab throughout 2024. Patients were both naïve and experienced with biologics or Janus kinase inhibitors (bio/JAKi-naïve or -experienced). The primary outcome for disease severity and therapeutic response was measured using the Eczema Area and Severity Index (EASI). Secondary outcomes included the Dermatology Life Quality Index (DLQI), itch- and sleep-numerical rating scales (NRS), body surface area (BSA), Investigator Global Assessment (IGA), SCORing Atopic Dermatitis (SCORAD), and Patient-Oriented Eczema Measure (POEM). Atopic Dermatitis Control Tool (ADCT) and minimal disease activity (MDA) were used to estimate disease control, and Hospital Anxiety and Depression Scales to monitor mental health status.

Results

At week 16, benefits in disease severity were observed for EASI (− 15.8 ± 9.4, p < 0.0001) and EASI head and neck (− 2.0 ± 1.7, p < 0.0001). QoL significantly improved in 70% of patients (DLQI reduction of − 12.6 ± 9.3, p < 0.0001), accompanied by decreased pruritus (Itch-NRS reduction of − 4.6 ± 3.2, p < 0.0001) and better sleep quality (sleep-NRS reduction of − 4.1 ± 3.4, p < 0.0001). A 76% reduction in BSA score was recorded, 85% of subjects improved their IGA index, with 62% achieving a score of 0–1, and SCORAD and POEM assessments significantly improved (p < 0.0001). Patients perceived a better control of the disease (ADCT, − 10.9 ± 7.1, p < 0.0001), and 14% of patients achieved MDA. Anxiety and depression levels decreased. Four mild adverse events were registered.

Conclusions

This is one of the first real-world multicenter studies in a predominantly adult white population showing that lebrikizumab is effective, safe and improves symptoms, QoL, and mental health in moderate-to-severe AD bio/JAKi-naïve and -experienced patients.